Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutation

8 Mar 2020

Abstract excerpt

Limited clinical application of antibody-drug conjugates (ADCs) targeting tumor associated antigens (TAAs) is usually caused by on-target off-tumor side effect. Tumor-specific mutant antigens (TSMAs) only expressed in tumor cells which are ideal targets for ADCs. In addition, intracellular somatic mutant proteins can be presented on the cell surface by human leukocyte antigen class I (HLA I)molecules forming...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33363632
DOI: 10.1016/j.ajps.2020.01.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutationPMID 33363632Read ↗

Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors.Semantic proximity Read ↗

Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors.Semantic proximity Read ↗

Overcoming immune evasion from post-translational modification of a mutant KRAS epitope to achieve TCR-T cell-mediated antitumor activitySemantic proximity Read ↗

T cell receptor mimic antibodies for cancer therapySemantic proximity Read ↗

Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager.Semantic proximity Read ↗

Identification of novel KRASG12D neoantigen specific TCRs and a strategy to eliminate off-target recognitionSemantic proximity Read ↗

Human cancer germline antigen-specific cytotoxic T cell—what can we learn from patientSemantic proximity Read ↗

An integrated in silico-in vitro workflow for discovering high-affinity, selective antibodies to the KRAS(G12D)-MHC I complexSemantic proximity Read ↗

Recent progress of aptamer‒drug conjugates in cancer therapySemantic proximity Read ↗

P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy.Semantic proximity Read ↗

Principles and Current Clinical Landscape of Multispecific Antibodies against CancerSemantic proximity Read ↗

Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.